Delayed Plaque Morphology in Patients With STEMI After Thrombus Aspiration During Primary PCI (STEMI-OCT)

March 9, 2015 updated by: Jian'an Wang,MD,PhD

Evaluation of Delayed Plaque Morphology by Optical Coherence Tomography (OCT) in Patients With Acute ST Segment Elevated Myocardial Infarction (STEMI) After Thrombus Aspiration During Primary Percutaneous Intervention (PCI)

The purpose of this study is to characterize the plaque morphology in patients with acute STEMI by OCT after aspiration thrombectomy.

Study Overview

Detailed Description

Current guideline for treating acute STEMI is primarily PCI and stent placement in the infarct-related coronary artery. But, the underlying plaque morphology is not routinely identified due to the limited resolution of conventional imagine modalities. However, autopsy studies have shown that there are different atherosclerotic plaque morphologies involving in acute thrombotic occlusion of coronary arteries other than atherosclerotic plaque rupture, such as plaque erosion, calcified nodule, etc. Some studies have suggested that PCI and stenting might not always be necessary in about 30 - 40% of ACS patients, and an alternative treatment strategy is needed for these patients based on the characteristics of plaque morphology.

100 subjects who meet the inclusion/exclusion criteria will undergo emergent angiography and followings: If no thrombus was observed, OCT examination will be performed in the target vessel;

If thrombosis was confirmed, the subject will undergo manual aspiration thrombectomy and antiplatelet therapy, and TIMI flow will be assessed:

If TIMI flow grade < 3, the subject will receive stent implantation as the standard of care followed by OCT examination; If TIMI flow grade of 3, the subject will not receive stent implantation but will be sent to CCU for monitoring and antiplatelet treatment, and have a repeat angiography and OCT examination at Day 7; within the 7days post STEMI, ischemia-driven angiography and/or PCI are allowed, and an OCT examination will be performed in these subject before PCI.

Patients without undergoing initial stent implantation will have scheduled 30-day and 12-month follow-ups for clinical outcomes.

Study Type

Observational

Enrollment (Anticipated)

100

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

patients with acute STEMI

Description

Inclusion Criteria:

  1. Clinical inclusion criteria:

    • Age > 18 years
    • Onset of STEMI > 30 minutes, but < 12 hours
    • ST segment elevation in at least 2 contiguous leads of≥ 1mm or newly developed LBBB on ECG
    • Willing and able to provide informed consent
  2. Angiographic inclusion criteria:

    • Having at least one infarct-related coronary artery, of which
    • The Culprit lesion is suitable for stenting;
    • The reference diameter of culprit vessel is ≥ 2.5 mm but ≤ 4 mm;
    • The TIMI flow is ≤ 1 in culprit lesion segment prior to guide wire crossing
    • No excessive tortuosity and calcification in the culprit lesion segment that allowing stent implantation

Exclusion Criteria:

1. Clinical exclusion criteria:

  1. Contraindicating to any concomitant study medications
  2. Having cardiogenic shock with hemodynamic instability
  3. A history of bleeding diathesis or known coagulopathy
  4. A history of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months; or a history of intracranial tumor, aneurysm or arteriovenous malformations; or a history of active peptic ulcer or active gastrointestinal (GI) bleeding within the past 2 months; or planned major procedure within 6 weeks; or known platelet count < 100,000 /mm3 or Hb < 10 g/dL
  5. Planned surgery which may cause discontinuation of ADP-receptor antagonist
  6. Other serious illness (e.g., cancer) that may reduce life expectancy to less than 1 year
  7. Repeated MI within 7 days of hospitalization for acute MI

    • Angiographic exclusion criteria:

      • Bifurcated lesion unable to identify the culprit lesion
      • The culprit lesion is located in the left main artery
      • Diffusive lesions without distinguishable culprit lesion
      • Previous stent implantation in the culprit lesion segment or STEMI caused by stent thrombosis
      • Likely CABG procedure within 30 days

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
plaque morphology by OCT
Time Frame: at the 7th day post PCI/aspiration thrombectomy
at the 7th day post PCI/aspiration thrombectomy

Secondary Outcome Measures

Outcome Measure
Time Frame
Re-hospitalization due to cardiac symptoms
Time Frame: 30 days & 12 months
30 days & 12 months
Myocardial infarction related to the target vessel
Time Frame: 30 days & 12 months
30 days & 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2015

Primary Completion (Anticipated)

April 1, 2017

Study Completion (Anticipated)

October 1, 2017

Study Registration Dates

First Submitted

January 15, 2015

First Submitted That Met QC Criteria

March 9, 2015

First Posted (Estimate)

March 10, 2015

Study Record Updates

Last Update Posted (Estimate)

March 10, 2015

Last Update Submitted That Met QC Criteria

March 9, 2015

Last Verified

March 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myocardial Infarction

Clinical Trials on Primary Percutaneous Intervention

3
Subscribe